Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity.

Ben-Efraim S.

Curr Drug Targets. 2001 Jun;2(2):197-212. Review.

PMID:
11469719
2.

Release of tumor necrosis factor-alpha and prostanoids in whole blood cultures after in vivo exposure to low-dose aspirin.

Beckmann I, Ben-Efraim S, Vervoort M, Wallenburg HC.

Mediators Inflamm. 2001 Apr;10(2):81-8.

3.

Use of xenogenized (modified) tumor cells for treatment in experimental tumor and in human neoplasia.

Ben-Efraim S, Bizzini B, Relyveld EH.

Biomed Pharmacother. 2000 Jun;54(5):268-73. Review.

PMID:
10917465
4.

Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases.

Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, Ben-Efraim S, Spirer Z.

Int J Immunopharmacol. 1999 Nov;21(11):759-75.

PMID:
10576621
5.

Immunopotentiating and immunotherapeutic effects of thymic hormones and factors with special emphasis on thymic humoral factor THF-gamma2.

Ben-Efraim S, Keisari Y, Ophir R, Pecht M, Trainin N, Burstein Y.

Crit Rev Immunol. 1999;19(4):261-84. Review.

PMID:
10530429
6.

THF-gamma 2-mediated reduction of pulmonary metastases and augmentation of immunocompetence in C57BL/6 mice bearing B16-melanoma.

Ophir R, Moalem G, Pecht M, Shashoua M, Rashid G, Ben-Efraim S, Trainin N, Burstein Y, Keisari Y.

J Immunother. 1999 Mar;22(2):103-13.

PMID:
10093035
7.

One hundred years of cancer immunotherapy: a critical appraisal.

Ben-Efraim S.

Tumour Biol. 1999 Jan-Feb;20(1):1-24. Review.

PMID:
9858871
8.

Interleukin-6 and interleukin-6 receptor secretion by chronic lymphatic leukaemia and normal B lymphocytes: effect of PMA and PWM.

Drucker I, Klajman A, Revel M, Manor Y, Ben-Efraim S, Novick D.

Mediators Inflamm. 1997;6(2):147-53.

9.

Cancer immunotherapy: potential involvement of mediators.

Ben-Efraim S.

Mediators Inflamm. 1997;6(3):163-73.

10.

Inhibition of murine Lewis lung carcinoma metastases by combined chemotherapy and intranasal THF-gamma 2 immunotherapy.

Rashid G, Ophir R, Pecht M, Lourie S, Meshorer A, Ben-Efraim S, Trainin N, Burstein Y, Keisari Y.

J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):324-33.

PMID:
8941872
11.

Cancer immunotherapy: hopes and pitfalls: a review.

Ben-Efraim S.

Anticancer Res. 1996 Sep-Oct;16(5B):3235-40. Review.

PMID:
8920797
12.

Secretion of suppressor factors by EBV infected B cell lines.

Drucker I, Ben-Efraim S, Klajman A.

Anticancer Res. 1996 Sep-Oct;16(5A):2857-61.

PMID:
8917398
13.

Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases.

Shahar I, Fireman E, Topilsky M, Grief J, Kivity S, Spirer Z, Ben Efraim S.

Clin Immunol Immunopathol. 1996 Jun;79(3):244-51.

PMID:
8635282
14.

Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.

Ophir R, Pecht M, Keisari Y, Rashid G, Lourie S, Meshorer A, Ben-Efraim S, Trainin N, Burstein Y.

Immunopharmacol Immunotoxicol. 1996 May;18(2):209-36.

PMID:
8771368
15.

Induction of macrophage antitumor activity by a mycobacterial fraction. In vivo and in vitro studies.

Rashid G, Gittel H, Ben-Efraim S.

Anticancer Res. 1994 May-Jun;14(3A):1083-7.

PMID:
8074454
16.

Modulation of antitumour activity of macrophages by regulation of eicosanoids and cytokine production.

Ben-Efraim S, Bonta IL.

Int J Immunopharmacol. 1994 May-Jun;16(5-6):397-9.

PMID:
7927985
17.

Activation in vitro of peritoneal macrophages by a nocardia fraction.

Ben-Efraim S, Rashid G, Gittel H, Tax C, Ciorbaru RB.

Anticancer Res. 1994 Mar-Apr;14(2A):449-52.

PMID:
8017846
18.

Differential Proliferative Characteristics of Alveolar Fibroblasts in Interstitial Lung Diseases: Regulative Role of IL-1 and PGE(2).

Fireman E, Ben Efraim S, Greif J, Peretz H, Kivity S, Topilsky M, Rodrig Y, Yellin A, Apte RN.

Mediators Inflamm. 1994;3(6):445-52.

19.

Therapeutical effect of activated human macrophages on a human tumor line growing in nude mice.

Ben-Efraim S, Tak C, Romijn JC, Fieren MJ, Bonta IL.

Med Oncol. 1994;11(1):7-12.

PMID:
7921926
20.

Involvement of inflammatory mediators in macrophage antitumor activity.

Bonta IL, Ben-Efraim S.

J Leukoc Biol. 1993 Dec;54(6):613-26. Review.

PMID:
8245715
21.

Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: a possible mechanism of defence.

Bomstein Y, Ophir R, Harshemes H, Ben-Efraim S.

Anticancer Res. 1993 Nov-Dec;13(6A):2125-9.

PMID:
8297124
23.

Suppressive mechanisms of alveolar macrophages in interstitial lung diseases: role of soluble factors and cell-to-cell contact.

Fireman E, Ben-Efraim S, Spinrad S, Topilsky M, Greif J.

Eur Respir J. 1993 Jul;6(7):956-64.

PMID:
8370444
24.

Activity of human peritoneal macrophages against a human tumor: role of tumor necrosis factor-alpha, PGE2 and nitrite, in vitro studies.

Ben-Efraim S, Tak C, Fieren MJ, Romijn JC, Beckmann I, Bonta IL.

Immunol Lett. 1993 Jul;37(1):27-33.

PMID:
8225404
25.

Protective effect of diclofenac sodium against endotoxic shock in anaesthetized pigs.

Mózes T, Heiligers JP, Tak CJ, Zijlstra FJ, Ben-Efraim S, Saxena PR, Bonta IL.

Prostaglandins Leukot Essent Fatty Acids. 1993 Feb;48(2):193-200.

PMID:
8446657
26.

Adjuvants--a balance between toxicity and adjuvanticity.

Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK.

Vaccine. 1993;11(3):293-306. Review.

PMID:
8447157
27.

A comparison between two methods for measuring tumor necrosis factor in biological fluids.

Garrelds IM, Zijlstra FJ, Tak CJ, Bonta IL, Beckmann I, Ben-Efraim S.

Agents Actions. 1993;38 Spec No:C89-91.

PMID:
8317331
28.
29.

Immunosuppression in vitro and in vivo by supernatants from murine lymphoma cell lines.

Klajman A, Drucker I, Zan-Bar I, Mekori Y, Ben-Efraim S.

Anticancer Res. 1992 May-Jun;12(3):741-7.

PMID:
1535768
30.
31.

Prostaglandin E2 inhibits the release of tumor necrosis factor-alpha, rather than interleukin 1 beta, from human macrophages.

Fieren MW, van den Bemd GJ, Ben-Efraim S, Bonta IL.

Immunol Lett. 1992 Jan;31(1):85-90.

PMID:
1548034
32.

Use of glutaraldehyde for preparation of immunogenic compounds.

Ben-Efraim S.

Vaccine. 1991 Dec;9(12):913. No abstract available.

PMID:
1811377
33.
34.

Platelet activating factor is one of the mediators involved in endotoxic shock in pigs.

Mózes T, Heiligers JP, Tak CJ, Zijlstra FJ, Ben-Efraim S, Saxena PR, Bonta IL.

J Lipid Mediat. 1991 Nov;4(3):309-25.

PMID:
1764577
35.

Tumour necrosis factor in inflammation: relation to other mediators and to macrophage antitumour defence.

Bonta IL, Ben-Efraim S, Mózes T, Fieren MW.

Pharmacol Res. 1991 Aug;24(2):115-30. Review. No abstract available.

PMID:
1749743
36.

Cell-free supernatants of sarcoid alveolar macrophages suppress proliferation of sarcoid alveolar fibroblasts.

Fireman E, Ben Efraim S, Messer G, Dabush S, Greif J, Topilsky M.

Clin Immunol Immunopathol. 1991 Jun;59(3):368-78.

PMID:
2029791
37.
38.

Serum levels of tumor necrosis factor determine the fatal or non-fatal course of endotoxic shock.

Mózes T, Ben-Efraim S, Tak CJ, Heiligers JP, Saxena PR, Bonta IL.

Immunol Lett. 1991 Feb;27(2):157-62.

PMID:
2026458
39.
40.

Appearance of the T-cell marker CD8 on B chronic lymphatic leukemia cells in long-term cultures.

Farkas R, Ben-Efraim S, Manor Y, Zan-Bar I, Klajman A.

Cancer Immunol Immunother. 1991;34(3):181-5.

PMID:
1836750
41.

Involvement of prostaglandins and cytokines in antitumor cytostatic activity of human peritoneal macrophages.

Bonta IL, Ben-Efraim S, Tak C, Fieren MW, van den Bemd GJ.

Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:879-82. No abstract available.

PMID:
1825430
42.

Inflammation amplifies the antitumor cytostasis by human peritoneal macrophages.

Ben-Efraim S, Tak C, Fieren MJ, Van den Bemd GJ, Bonta IL.

Med Oncol Tumor Pharmacother. 1991;8(2):87-94.

PMID:
1749305
43.
44.

Interactions between inflammatory mediators in expression of antitumor cytostatic activity of macrophages.

Bonta IL, Ben-Efraim S.

Immunol Lett. 1990 Sep;25(4):295-301. Review. Erratum in: Immunol Lett 1990 Dec;26(3):297.

PMID:
2123474
45.

Immunological reactivity to a mycobacterial fraction is associated with nonspecific suppression of immunological responsiveness in vivo.

Halperin D, Reuben C, Rashid G, Ben-Efraim S, Weiss DW.

In Vivo. 1990 Jul-Aug;4(4):263-8.

PMID:
2103371
46.

A synthetic thymic hormone, THF-gamma 2, repairs immunodeficiency of mice cured of plasmacytoma by melphalan.

Ophir R, Pecht M, Rashid G, Halperin D, Lourie S, Burstein Y, Ben-Efraim S, Trainin N.

Int J Cancer. 1990 Jun 15;45(6):1190-4.

PMID:
2141006
47.

Macrophage cytokines render WEHI-3B tumor cells susceptible to cytostasis by prostaglandins.

Ben-Efraim S, Tak C, Bonta IL.

Prostaglandins Leukot Essent Fatty Acids. 1990 Jun;40(2):163-7.

PMID:
2385615
48.

Leukotriene C4 is an essential 5-lipoxygenase intermediate in A23187-induced macrophage cytostatic activity against P815 tumor cells.

van Hilten JA, Ben Efraim S, Zijlstra FJ, Bonta IL.

Prostaglandins Leukot Essent Fatty Acids. 1990 Apr;39(4):283-90.

PMID:
2112758
49.

Calcium-ionophore A23187 induces dual changes in the release of 5-lipoxygenase and cyclooxygenase products by macrophages.

van Hilten JA, Ben Efraim S, Bonta IL.

Arch Int Pharmacodyn Ther. 1990 Mar-Apr;304:55-63.

PMID:
2173505
50.

Induction of protective antitumor immune response against a murine plasmacytoma not curable by alkylating-drug treatment.

Ophir R, Jackman A, Relyveld EH, Ben-Efraim S.

Anticancer Res. 1990 Jan-Feb;10(1):231-5.

PMID:
2334133

Supplemental Content

Loading ...
Support Center